GC LabCell and Feldan Therapeutics announce license agreement to develop next-generation NK cells for immunotherapy using Feldan Shuttle technology
SEOUL, South Korea and QUÉBEC CITY, June 27, 2018 /CNW Telbec/ – GC LabCell (hereafter “GCLC”) and Feldan Therapeutics (hereafter “Feldan”) announced an agreement today granting GCLC exclusive rights to use the Feldan Shuttle platform in developing and manufacturing genetically engineered Natural Killer cells (“NK cells”) for human oncology.
GCLC has an international expertise in the development of NK-cell-based therapeutics, while Feldan has introduced an innovative peptide-based delivery system that enables highly efficient transduction of proteins into mammalian cells (the Feldan Shuttle platform). Since 2016, the two companies have collaborated to develop off-the-shelf primary NK cells that are hyperactive on tumor cells.
This post is also available in: Français (French)